Boserolimab Biosimilar – Anti-CD27L receptor mAb – Research Grade from ProteoGenix; catalogue PX-TA2104; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Boserolimab Biosimilar, also known as Anti-CD27L receptor monoclonal antibody (mAb), is a novel therapeutic agent that targets the CD27L receptor and has shown promising results in pre-clinical studies. This biosimilar is a research grade antibody that is being developed as a potential treatment for various diseases, including cancer and autoimmune disorders. In this article, we will discuss the structure, activity, and potential applications of Boserolimab Biosimilar in detail.
Boserolimab Biosimilar is a monoclonal antibody that specifically targets the CD27L receptor, a protein that is expressed on the surface of certain immune cells. It is a fully humanized IgG1 antibody, meaning that it is derived from human cells and has a similar structure to naturally occurring antibodies in the body. The antibody consists of two heavy chains and two light chains, which are linked together by disulfide bonds. The variable regions of the antibody are responsible for binding to the CD27L receptor, while the constant regions are responsible for mediating the effector functions of the antibody.
Boserolimab Biosimilar works by binding to the CD27L receptor, which is a co-stimulatory molecule that is involved in the activation and proliferation of T cells. By blocking the interaction between CD27L and its receptor, Boserolimab Biosimilar inhibits the activation and proliferation of T cells, leading to a decrease in the immune response. This mechanism of action makes it a potential treatment for diseases where an overactive immune response is involved, such as autoimmune disorders and certain types of cancer.
Boserolimab Biosimilar has shown promising results in pre-clinical studies for the treatment of various diseases, including cancer and autoimmune disorders. In cancer, Boserolimab Biosimilar has been shown to inhibit the growth of tumor cells and enhance the anti-tumor immune response. It has also been shown to increase the effectiveness of other cancer treatments, such as chemotherapy and radiation therapy.
In autoimmune disorders, Boserolimab Biosimilar has been shown to reduce the production of autoantibodies and decrease the activity of immune cells that are responsible for attacking the body’s own tissues. This makes it a potential treatment for diseases such as rheumatoid arthritis, lupus, and multiple sclerosis.
Boserolimab Biosimilar is currently in the early stages of development and has not yet been approved for clinical use. However, it has shown promising results in pre-clinical studies and is expected to undergo further testing in clinical trials in the future.
Boserolimab Biosimilar is a novel therapeutic agent that targets the CD27L receptor and has shown promising results in pre-clinical studies. Its unique mechanism of action makes it a potential treatment for various diseases, including cancer and autoimmune disorders. With further research and clinical trials, Boserolimab Biosimilar has the potential to become an important addition to the treatment options for these diseases.
ProteoGenix catalogue number PX-TA2104. For research use only.
Target: Boserolimab Biosimilar – Anti-CD27L receptor mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Boserolimab Biosimilar – Anti-CD27L receptor mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
